|
Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study. |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences; Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine |
|
|
Employment - Foundation Medicine; Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Roche/Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Patent on IHC |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche Pharma AG |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Research Funding - Foundation Medicine |
|
|
Employment - Foundation Medicine; Partners Healthcare |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics |
Research Funding - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Research Funding - Celgene (Inst); Lilly (Inst); Puma Biotechnology (Inst) |
|
|
Employment - Foundation Medicine; SeqTech Diagnostics (I) |
|
Stock and Other Ownership Interests - GenomOncology; Personalis |
|
Consulting or Advisory Role - GenomOncology, Inc; Personalis; Roche |
Research Funding - GenomOncology |
Patents, Royalties, Other Intellectual Property - Royalties from GenomOncology for licensing of MyCancerGenome content |
Travel, Accommodations, Expenses - Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen |
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst) |